NAD+: effects, precursors and the state of the research

This article is for information only and does not replace medical advice, diagnosis or treatment. Statements about prescribing and availability refer to the United States. The original source describes NAD+ formulations as prescription products.

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme that the body makes from precursors such as tryptophan, nicotinamide, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). It cycles between its oxidized form (NAD+) and its reduced form (NADH), carrying electrons from one metabolic reaction to the next. Beyond this redox role, NAD+ serves as a substrate for three enzyme families and is used up in the process. These enzyme families regulate genomic integrity and cellular stress responses: sirtuins (SIRT1-7), poly(ADP-ribose) polymerases (PARPs) and cyclic ADP-ribose synthases (CD38/BST1). Plasma NAD+ concentrations are measurably lower in older adults than in younger controls, a finding documented across several tissue types. Source

How NAD+ works in the body

Cellular energy production and mitochondrial function

NAD+ is the main electron acceptor in glycolysis and the citric acid cycle. In both pathways, metabolic intermediates hand electrons to NAD+, turning it into NADH. NADH then delivers those electrons to the mitochondrial electron transport chain, where they drive ATP synthesis. A 2020 review by Covarrubias and Perrone in Nature Reviews Molecular Cell Biology documents that declining mitochondrial NAD+ availability is mechanistically linked to lower ATP production, impaired fatty acid oxidation and features of metabolic dysfunction in aging tissue. The relationship between NAD+ and mitochondrial function runs both ways: impaired mitochondria use up NAD+ faster, which speeds up the cycle. That makes NAD+ availability a rate-limiting factor for cellular energy production rather than a simple downstream marker of metabolic health. Source

Sirtuin activation and gene regulation

Sirtuins are a family of seven NAD+-dependent deacylases that regulate gene expression, DNA repair and metabolic adaptation. SIRT1 and SIRT3 are the ones most often studied in the context of aging. They need NAD+ as a substrate that is consumed in the reaction, not as a cofactor: each catalytic cycle uses up one molecule of NAD+. A 2020 review by Katsyuba and Romani in Nature Metabolism describes how falling NAD+ availability reduces sirtuin activity and disrupts the transcriptional programs that control mitochondrial biogenesis, inflammation control and stress resistance. This pathway is one of the main reasons NAD+ supplementation is studied in longevity research. Calorie restriction, which reliably extends lifespan in animal models, raises NAD+ and activates sirtuins, which suggests a plausible mechanistic link. Source Source

DNA repair via PARP enzymes

PARP1 and PARP2 are enzymes in the cell nucleus that detect single-strand DNA breaks and coordinate their repair. Each activation event consumes several NAD+ molecules. When DNA damage is extensive, as with oxidative stress, radiation exposure or aging, PARP activation can deplete cellular NAD+ substantially. A 2023 study by Munk and Merchut-Maya in Nature Cell Biology tested exogenous NAD+ in several human and mouse cell lines (including MRC5, BJ, HeLa and T98G) at concentrations from 0.64 µM to 2 mM. Short-term incubation increased pyrimidine biosynthesis and mitochondrial electron transport, while longer 24-hour exposure at 2 mM depleted pyrimidine pools, caused purines to accumulate, activated the replication stress response and triggered cell cycle arrest. The takeaway: dose and duration matter. Separately, a 2025 review by Bohr in Aging Cell summarized clinical data on rare premature aging syndromes with defective DNA repair. In Werner syndrome (N=9), 1,000 mg/day of NR for 52 weeks raised plasma NAD+ by about 140%, compared with a 4% decline on placebo, and reduced arterial stiffness and the size of skin ulcers. In ataxia telangiectasia (N=24), 25 mg/kg/day of NR for 4 months improved ataxia scores, and the effect reversed after the supplement was stopped. This is early clinical evidence that PARP-driven NAD+ depletion matters clinically beyond animal models. Source Source

Nerve cell resilience and brain aging

Neurons have high energy demands and limited capacity to regenerate, which makes NAD+ availability in the central nervous system especially important. A 2019 review by Lautrup and Sinclair in Cell Metabolism described NAD+ as playing a key role in how neurons withstand metabolic and oxidative stress, with falling levels linked to the patterns of vulnerability seen in neurodegenerative diseases. The randomized NR-SAFE trial, published in 2023 by Berven and Kverneng in Nature Communications, included 20 people with Parkinson’s disease: 10 received 3,000 mg/day of NR for 4 weeks and 10 received placebo. The NR group showed an average drop of 10.7 points in the total MDS-UPDRS score, compared with no change in the placebo group (p = 0.024 between groups), while blood NAD+ rose about 3.7-fold. All 42 adverse events reported across both groups were rated mild, although the small sample and single-center design limit how far the results can be generalized. It is one of the few controlled human trials of NAD+ precursors in a group with a neurological disease. Source Source

Redox balance and inflammation control

The NAD+/NADH ratio is a direct readout of the cell’s redox state. When NAD+ falls relative to NADH, the cell’s redox balance shifts toward a more reduced state. This shift switches on pro-inflammatory signaling pathways and weakens the response to oxidative stress. A comprehensive 2019 review by Braidy and Berg in Antioxidants and Redox Signaling documented the biochemical links between NAD+ redox balance, NF-kB inflammatory signaling and the buildup of reactive oxygen species across several tissue types. CD38, an NAD+-consuming enzyme that increases with age and in inflammatory conditions, is a major driver of age-related NAD+ decline, independent of the body’s capacity to make NAD+. Higher inflammatory markers are associated with faster NAD+ breakdown, creating a feedback loop that matters for people with chronic low-grade inflammation. Source Source

What the research shows about effectiveness

NMN supplementation: dose-dependent rise in blood NAD+

The strongest human studies on NAD+ precursors involve NMN. A 2022 multicenter RCT by Yi and Maier in GeroScience enrolled 80 healthy middle-aged adults (average age 47). They were randomly assigned to NMN at 300 mg/day, 600 mg/day, 900 mg/day or placebo and treated for 60 days. All NMN groups showed statistically significant increases in blood NAD+ concentrations on day 30 and day 60 compared with placebo and with baseline (all p ≤ 0.001). In the 600 mg group, levels climbed from about 8 nM at the start to 39 nM on day 30 and 45 nM on day 60, roughly a fivefold increase. The 600 mg and 900 mg groups reached a clearly larger NAD+ rise than the 300 mg group, suggesting that the maximum effect sits at 600 mg/day. No serious adverse events were reported at any dose. A separate 2022 RCT by Okabe and Yaku in Frontiers in Nutrition randomized 30 healthy adults to 250 mg/day of NMN or placebo for 12 weeks. NMN roughly doubled whole-blood NAD+ levels compared with placebo after 4 weeks (p < 0.001), the increase held through 12 weeks, and there were no abnormal findings on safety labs or side effects. In a 2022 study by Pencina and Lavu in the Journal of Gerontology, Series A, 32 middle-aged and older adults were randomized to MIB-626 (microcrystalline NMN) at 1,000 mg once daily, 1,000 mg twice daily or placebo for 14 days. Blood NMN rose in a dose-dependent way, 1.7-fold and 3.7-fold above baseline in the once-daily and twice-daily groups, with matching NAD+ rises of about twofold (once daily) and threefold (twice daily) above baseline, and with no significant difference in adverse events compared with placebo. Across all of these studies, the rise in blood NAD+ is reproducible. What they could not show is whether higher blood NAD+ in humans leads to the anti-aging effects seen in animal models. Source Source Source

NR supplementation: safety and early hints of cardiovascular effects

Nicotinamide riboside (NR) has an evidence profile similar to NMN. A 2018 crossover RCT by Martens and Denman in Nature Communications included 24 healthy middle-aged and older adults who took 1,000 mg/day of NR or placebo over two 6-week periods. NR raised whole-blood NAD+ by about 60% compared with placebo (p = 0.048). In an exploratory analysis, systolic blood pressure in participants with elevated baseline values was about 9 mmHg lower after NR than after placebo. There was also a trend toward lower pulse wave velocity between the carotid and femoral arteries. The study was not designed to confirm cardiovascular outcomes. A 2018 paper by Johnson and Imai in F1000Research concluded that dysfunction in NAD+ biosynthesis contributes to age-related disease and that supplementing NAD+ intermediates has potential as an anti-aging intervention, while acknowledging that evidence from human studies was still limited at the time. In a 2019 safety RCT by Conze and Brenner in Scientific Reports, 140 healthy overweight adults were randomized to 100, 300 or 1,000 mg/day of NR or placebo for 8 weeks, with dose-dependent whole-blood NAD+ increases of 22%, 51% and 142%, respectively. No flushing was reported. Side effect rates did not differ significantly between NR and placebo, and no rise in LDL cholesterol or disruption of one-carbon metabolism was observed. Source Source Source

Overall assessment of the evidence

A 2026 PRISMA-guided systematic review by Gallagher and Emmanuel in Ageing Research Reviews examined the literature from 2010 to 2025 and included 113 eligible studies covering all NAD+ precursor forms: 33 human intervention studies (28 randomized, 5 non-randomized) and 80 rodent studies. The review found clear biological activity: supplementation consistently raises blood NAD+, in a dose-dependent way, across all study populations. Clinical benefit for age-related endpoints, however, including improvements in physical function, cognitive performance or metabolic endpoints, remained unclear on the available evidence. Human results were described as inconsistent: often there was no effect, or an effect showed up only on individual endpoints. Because the study designs varied so widely, no pooled quantitative synthesis was performed. The authors noted that most positive signals come from animal models or from human studies that measured surrogate endpoints (blood NAD+) rather than clinical outcomes. The review therefore separates biological activity from a clinical benefit that has not yet been clearly established. Source

How do NAD+ and NMN differ?

NAD+ and NMN act on the same cellular systems, but they differ fundamentally in how they get into cells, in how bioavailable they are depending on the route of administration, and in their regulatory classification.

NMN is a direct biosynthetic precursor of NAD+, one step before NAD+ in the salvage pathway, the route by which the body recycles NAD+ building blocks. It is absorbed intact and converted into NAD+ inside the cell by the enzyme NMNAT. The US source describes oral NMN as an over-the-counter dietary supplement. Other forms of administration are also being studied. A 2026 retrospective comparison by Reyna and Heinzen in Frontiers in Aging documented 500 mg of IV NAD+ (n=6) or 500 mg of IV NR (n=8) given on four consecutive days. All of the NAD+ recipients (100%) had moderate to severe gastrointestinal discomfort, chest pressure and a raised heart rate. By contrast, 62.5% of the NR recipients reported only mild tingling and mild cramps. Symptoms resolved in both groups once the infusion was finished; follow-up lasted 30 days. Source Source

Giving NAD+ directly, especially by the intravenous or intranasal route, skips precursor conversion entirely and raises plasma NAD+ faster than oral precursors do. In a 2019 pilot study by Grant and Berg in Frontiers in Aging Neuroscience, 8 healthy men (with 3 saline controls) received 750 mg of NAD+ by IV infusion over 6 hours. Plasma NAD+ rose 398% above baseline by the end of the infusion, with parallel increases in nicotinamide (409%), ADPR (393%) and methylnicotinamide (350%). Changes in these metabolites, however, appeared only after the 2-hour mark, and levels began to fall about 2 hours after the infusion. Intranasal administration is a more practical option for outpatient use: it avoids the time and cost of an IV infusion and may offer higher CNS bioavailability than the oral route, although the pharmacokinetic evidence for nose-to-brain transport so far comes from animal studies. Preclinical reviews describe the pharmacokinetic reasoning behind intranasal use in neurological conditions, but direct human evidence of NAD+ transport from the nose to the brain has not yet been published. Source

The practical difference: oral NMN and NR are accessible, have been studied in humans and have a well-characterized safety profile for raising blood NAD+. Intranasal NAD+ is being studied as a prescription alternative with possibly higher bioavailability. Using it requires an individual medical rationale. IV NAD+ produces the fastest and most complete systemic rise but has to be given in a clinical setting.

What forms of administration are there?

NAD+ and its precursors are available by several routes, each with different bioavailability, onset of action and requirements for access.

Intranasal NAD+ is an individually compounded prescription formulation given through the nasal lining, typically NAD+ in a buffered carrier solution. Intranasal administration offers rapid absorption through the nasal mucosa, potential direct access to the cerebrospinal fluid (the fluid around the brain and spinal cord) via olfactory pathways (shown preclinically in rat models with analogous compounds), and avoidance of the first-pass liver metabolism that limits the oral bioavailability of NAD+ itself. Dose and frequency are set by a physician.

IV NAD+ produces the fastest and most complete rise in plasma NAD+, but it has to be given in a clinical setting, takes several hours per session and, at higher doses, comes with temporary infusion reactions.

The US source classifies oral NMN and NR as over-the-counter dietary supplements. In controlled studies, at the doses tested (300–600 mg/day for NMN; 1,000 mg/day for NR in the NADPARK study and up to 3,000 mg/day in the NR-SAFE study), they repeatedly and measurably raise blood NAD+. Sublingual and liposomal formulations of NMN/NR are marketed with claims of higher bioavailability, but controlled comparisons with standard oral forms in human pharmacokinetic studies are limited.

Oral NAD+ itself has poor bioavailability because it is hydrolyzed in the gastrointestinal tract; most oral NAD+ is broken down to nicotinamide before it is absorbed. For raising NAD+ levels, oral precursors (NMN or NR) are more effective than oral NAD+ itself. Source

What side effects are known?

The safety profile of NAD+ supplementation has been characterized across several formulations and doses. Most reported side effects are mild and dose-dependent, and intravenous forms have a different tolerability profile from oral or intranasal use.

Common side effects across all formulations:

• Nausea or gastrointestinal discomfort (mainly with oral NMN/NR at higher doses; typically dose-dependent and self-limiting)

• Flushing or a feeling of warmth (more common at higher doses; less common with NR than with niacin precursors) Source

• Temporary headache (reported across all routes; usually resolves with dose adjustment)

• Irritation or a mildly stuffy nose (intranasal form; typically temporary)

Infusion-specific reactions (less common, but reported):

• Chest tightness, anxiety or palpitations during the infusion (often with faster infusion rates; manageable by slowing the infusion; if symptoms persist, stop the infusion and seek medical advice)

• Muscle cramps or jaw tension during the infusion (depends on the infusion rate; resolves after the infusion)

• Nausea or lightheadedness during or after the infusion, as documented in a 2026 retrospective study by Reyna and Heinzen in Frontiers in Aging Source

In the NR-SAFE trial, 10 people with Parkinson’s disease received 3,000 mg of NR per day for 4 weeks (another 10 received placebo). All 42 adverse events reported in both groups were rated mild, with no significant difference in frequency between the NR and placebo arms. Data on long-term safety beyond 8–16 weeks remain limited for most formulations. Before anything is prescribed, a physician reviews individual risk factors. Source

Who is NAD+ usually prescribed for?

Adults with documented NAD+ decline or related metabolic problems

Whether prescription NAD+ is an option is decided by a physician based on symptoms, medical history and relevant biomarkers. NAD+ decline cannot currently be measured with a standard clinical blood test, but related markers, such as a higher inflammatory burden, HbA1c trending toward the upper range and falling markers of cellular energy, provide useful context. Adults in their forties and older with fatigue, metabolic problems or an interest in longevity medicine may be evaluated. NAD+ is not FDA-approved for any indication. No other uses have been approved by the FDA. The safety and effectiveness of NAD+ for any use have not been established in adequate and well-controlled clinical studies reviewed by the FDA. A prescription rests on an individual medical assessment.

Certain neurological or metabolic conditions

The strongest human evidence for a benefit from NAD+ precursors comes from groups with documented disruptions in NAD+ biosynthesis pathways, such as rare premature aging syndromes with DNA repair defects. Findings from the NR-SAFE trial support tolerability in Parkinson’s disease, but effectiveness for this indication is still under study. Physicians in metabolic, functional or longevity medicine may also consider NAD+ in the context of insulin resistance, biomarker profiles for cellular aging and suspected problems with mitochondrial function. Suitability is assessed individually based on medical history and baseline tests.

Who should not use NAD+?

Before anything is prescribed, a physician assesses individual risks. The following are generally considered contraindications or conditions that call for additional clinical evaluation:

• Active malignancy: NAD+ broadly supports cellular energy and DNA repair mechanisms; possible effects on tumor cell metabolism have not been adequately studied in oncology populations. In active cancer, NAD+ is generally not prescribed without input from a specialist

• Pregnancy and breastfeeding: safety in these patient groups has not been established; avoid

• Severe kidney or liver impairment: the liver is involved in NAD+ metabolism, and impaired clearance may change the safety profile. eGFR and liver function should be assessed before treatment starts

• Known hypersensitivity to nicotinamide, niacin or related compounds: cross-reactivity has been reported; any previous reactions must be discussed with a physician before use

• Concurrent use of PARP inhibitors: NAD+ is the substrate that PARP enzymes consume; pharmacological PARP inhibition combined with NAD+ supplementation has not been studied in humans and may lead to unpredictable interactions

This list is not complete. Before anything is prescribed, a physician reviews medications, medical history and individual risk factors.

Which tests make sense before use?

No single biomarker directly measures tissue NAD+ levels in a standard clinical setting. Baseline tests provide a reference point for the metabolic and physiological systems that NAD+ affects most directly, and they supply the safety data a physician needs before prescribing a product.

• Fasting glucose and HbA1c: NAD+ plays a central role in glucose metabolism and insulin signaling. Elevated fasting glucose or HbA1c may reflect the metabolic dysfunction most often associated with age-related NAD+ decline. These markers set metabolic baselines that make changes during use interpretable.

• Fasting insulin: insulin sensitivity is closely tied to NAD+ and sirtuin signaling. A baseline fasting insulin value can flag early insulin resistance more sensitively than glucose or HbA1c alone, especially in people without established diabetes.

• hs-CRP: chronic low-grade inflammation drives CD38 activation, which consumes NAD+ and speeds up its breakdown. Elevated hs-CRP suggests that a person may be more likely to have lower baseline NAD+ because of inflammation-driven consumption. It also offers a reference point for tracking any anti-inflammatory response during supplementation. Source

• Comprehensive metabolic panel (CMP): covers liver function markers (ALT, AST, bilirubin) and kidney function markers (creatinine, eGFR, BUN), which are relevant for any prescription product. NAD+ precursor metabolism involves processing in the liver; raised liver enzymes or impaired kidney function affect prescribing decisions and dose selection.

• Vitamin B12: B12 is needed for one-carbon metabolism and methylation reactions, which are central to overall metabolic health. B2 and B6 (which serve as essential cofactors for the enzymes of the kynurenine pathway) are the B vitamins most directly involved in tryptophan-kynurenine-NAD+ biosynthesis, but B12 status influences methylation broadly and is a standard baseline marker for any metabolic intervention. A B12 baseline is especially relevant for older adults and people with a restricted diet. Source

• Complete blood count (CBC): provides a baseline for hematological health before any medication is prescribed. NAD+ affects red blood cell metabolism; this serves as a standard safety reference rather than a primary monitoring target.

• Lipid panel: niacin metabolism (which overlaps with NAD+ precursor pathways) can affect lipid profiles. Lipid values before treatment provide a reference that may be relevant depending on the precursor form and dose used. Source

Fasting glucose, HbA1c, fasting insulin, hs-CRP and a comprehensive metabolic panel are the most important markers for establishing a baseline before NAD+ use. They reflect the metabolic and inflammatory systems most directly affected by NAD+ availability, and they make changes during use clinically interpretable. For more on these markers, see the guide to biomarker testing for metabolic health.

What changes might lab results show?

Blood NAD+ is not a standard clinical lab test, but several downstream markers give indirect clues about a metabolic response. When use is supervised by a physician, fasting glucose and insulin are often checked as signs of metabolic change, along with HbA1c at 3-month intervals and hs-CRP as an inflammation marker. In the human RCT literature, blood NAD+ levels (measured in whole blood or PBMCs) are the most consistent biomarker of response to supplementation, rising in a dose-dependent way within 2–4 weeks of starting NMN or NR. Functional clinical endpoints such as fatigue, physical performance and cognitive performance have been reported as patient-reported outcomes in some studies, but objective biomarker correlations for these changes in humans have not yet been established. Changes are compared with pre-treatment values. This adds to interpretation against population reference ranges.

Baseline values help put later measurements in context. That is why relevant biomarkers are recorded before treatment and reassessed over time.

Frequently asked questions

What is the difference between NAD+ and NMN?

NMN (nicotinamide mononucleotide) is a direct biosynthetic precursor of NAD+, one enzymatic step before NAD+ in the salvage pathway. Oral NMN is absorbed and converted into NAD+ inside the cell by the enzyme NMNAT. Direct NAD+ administration (IV or intranasal) delivers the coenzyme itself, skipping precursor conversion, so plasma NAD+ rises faster and to higher levels than with oral precursors. The clinical significance of this difference in speed and peak in humans is still being studied. The US source describes oral NMN as a dietary supplement and intranasal NAD+ as an individually compounded formulation that requires a prescription. Source

Is IV NAD+ better than oral supplements?

IV NAD+ produces the fastest and highest rise in plasma NAD+ of any route: a 2019 pilot study by Grant and Berg found a 398% increase in plasma NAD+ after a 6-hour infusion of 750 mg in 8 healthy men. Oral NMN and NR repeatedly and measurably raise blood NAD+ in controlled studies, but more slowly and with lower peaks. Comparative studies have not settled whether the higher peak achieved with IV administration leads to better clinical outcomes than oral precursors. IV infusions also come with temporary side effects during administration that do not occur with oral forms. The right route depends on the clinical context and is decided by a physician. Source

How often are NAD+ infusions or intranasal products used?

There is no established standard protocol based on results from randomized trials. How often IV NAD+ infusions are given in clinical practice varies widely, from single sessions to weekly or monthly schedules, depending on the physician’s assessment and the patient’s response. Intranasal NAD+ dosing protocols for compounded formulations are also set by a physician. In the human RCT literature, oral NMN and NR have been studied with daily oral dosing over periods of 60 days to 12 weeks. Dose and frequency are set by a physician based on the clinical picture and baseline tests.

Is NAD+ FDA-approved?

NAD+ is not FDA-approved for any specific indication. It is a naturally occurring coenzyme found in all human cells. According to the US source, intranasal NAD+ is available by prescription through licensed 503A pharmacies, which prepare individual compounded formulations. Oral NMN and NR are classified as dietary supplements and are available without a prescription, although they are not FDA-approved drugs and their effectiveness claims have not been reviewed by the FDA. A prescription for an individual need follows the US rules on compounding. That is different from FDA approval.

What are the side effects of NAD+?

Side effects vary by route of administration. Oral NMN and NR are generally well tolerated; the most common reports are gastrointestinal discomfort, flushing and temporary headaches at higher doses. The NR-SAFE trial found no serious adverse events at 3,000 mg of NR per day over 4 weeks. IV NAD+ has a distinct tolerability profile: chest tightness, palpitations, nausea and muscle cramps are reported during the infusion and are managed by lowering the infusion rate. Intranasal NAD+ can cause temporary nasal irritation. Systematic long-term safety data beyond 12–16 weeks are limited for all formulations.

Can NAD+ improve energy and ease fatigue?

NAD+ is mechanistically central to mitochondrial ATP production, and less fatigue is among the most frequently reported subjective improvements in observational reports and some studies. Current human RCT results, however, mainly show that supplementation raises blood NAD+, rather than demonstrating objective improvements in energy production or fatigue as a clinical endpoint. The distinction matters: a rise in a surrogate biomarker does not confirm the clinical outcome. Studies measuring patient-reported fatigue have shown mixed results. People with documented metabolic dysfunction, mitochondrial problems or biomarker patterns of chronic fatigue may be the most suitable candidates for a medical evaluation.

Which blood tests should I have before starting NAD+?

The most important baseline markers are fasting glucose, HbA1c, fasting insulin, hs-CRP, a comprehensive metabolic panel (covering liver and kidney function), vitamin B12 and a complete blood count. These reflect the metabolic and inflammatory systems most strongly affected by NAD+ availability. They also establish the safety baseline needed before a physician prescribes an individual compounded formulation. The guide to energy biomarkers offers more context for understanding tests related to cellular energy.

Frequently asked questions

What is NAD+ and what does it do in the body?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. It carries electrons through glycolysis and the citric acid cycle and so drives ATP synthesis. It also serves as a substrate for sirtuins, PARPs and CD38 and is used up in the process. These enzymes control DNA repair and gene expression. Plasma NAD+ measurably declines with age across several tissue types, starting in early adulthood, and this is the central rationale for current supplementation research.

What is the difference between NAD+ and NMN?

NMN sits one biosynthetic step before NAD+: taken orally, it is converted into NAD+ inside the cell by the enzyme NMNAT, rather than delivering the coenzyme directly. Direct NAD+ by the intravenous or intranasal route skips this conversion and raises plasma NAD+ faster and to higher peaks. According to the US source, oral NMN is available without a prescription; intranasal NAD+ as an individual compounded formulation requires a prescription. Whether the faster rise leads to better clinical outcomes than oral precursors has not been shown.

Does NAD+ supplementation actually raise NAD+ levels in humans?

Yes. A rise in blood NAD+ is the most frequently replicated finding in human studies. A 2022 multicenter RCT in 80 healthy adults found that all NMN doses (300–900 mg/day) produced statistically significant increases compared with placebo; the 600 mg/day group reached roughly a fivefold increase. A 2019 NR study in 140 adults showed dose-dependent increases of 22% to 142%. It has not been established, however, whether these increases translate into clinical anti-aging outcomes.

Is NAD+ FDA-approved, and do I need a prescription?

NAD+ is not FDA-approved for any specific indication. According to the US source, intranasal NAD+ is available as an individual compounded formulation through licensed 503A pharmacies with a prescription. This rests on an individual medical decision and does not amount to FDA approval. The oral precursors NMN and NR are over-the-counter dietary supplements, but they are not FDA-approved drugs. Safety and effectiveness for any use have not been established in controlled clinical studies reviewed by the FDA.

What side effects do NAD+ supplements and infusions have?

Side effects vary by route. Oral NMN and NR are generally well tolerated; common reports include gastrointestinal discomfort, flushing and temporary headaches at higher doses. The NR-SAFE trial found no serious adverse events at a dose of 3,000 mg/day over 4 weeks. Intranasal NAD+ can cause temporary nasal irritation. IV NAD+ has a more pronounced profile (chest tightness, palpitations, nausea and cramps during the infusion), which is managed by slowing the infusion rate; symptoms usually resolve once it is finished.

Which blood tests should I have before starting NAD+ supplementation?

The core pre-NAD+ tests include fasting glucose, HbA1c, fasting insulin, hs-CRP and a comprehensive metabolic panel (liver and kidney function). These reflect the metabolic and inflammatory systems most strongly affected by NAD+ and provide the safety reference a physician needs before prescribing. Vitamin B12, a complete blood count and a lipid panel round out the baseline. Changes can be put in context by comparing them with pre-treatment values.

Who should not take NAD+ or NAD+ precursors?

Groups that call for particular caution include patients with active malignancy (effects on tumor cell metabolism are inadequately studied), people who are pregnant or breastfeeding (safety not established) and people with severe kidney or liver impairment. People with a hypersensitivity to nicotinamide or niacin compounds, and anyone taking PARP inhibitors, should tell their physician: this combination has not been studied in humans. Before any form of NAD+ is prescribed, a physician reviews medications and medical history.

Can NAD+ supplementation affect energy, fatigue or brain function?

NAD+ is mechanistically central to mitochondrial ATP production and neuronal resilience, and subjective improvements in energy are often reported in observational data. Current randomized trials mainly show a rise in blood NAD+. Whether this objectively improves energy or fatigue as clinical endpoints has not yet been clearly established. The NR-SAFE trial in 20 people with Parkinson’s disease showed a 10.7-point improvement on the MDS-UPDRS with 3,000 mg/day of NR compared with no change on placebo, although the sample was small.

This article is for information only and does not replace medical advice, diagnosis or treatment. Statements about prescribing and availability refer to the United States. The original source describes NAD+ formulations as prescription products.

Sources and references

Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD. Nature reviews. Molecular cell biology, 22(2), 119-141. https://doi.org/10.1038/s41580-020-00313-x Publication

PubChem (National Library of Medicine). (n.d.). Nadide (JAN/USAN/INN). https://pubchem.ncbi.nlm.nih.gov/compound/5893 Publication

Katsyuba E, Romani M, Hofer D, Auwerx J (2020). NAD. Nature metabolism, 2(1), 9-31. https://doi.org/10.1038/s42255-019-0161-5 Publication

Wang Y (2014). Molecular Links between Caloric Restriction and Sir2/SIRT1 Activation. Diabetes & metabolism journal, 38(5), 321-9. https://doi.org/10.4093/dmj.2014.38.5.321 Publication

Munk SHN, Merchut-Maya JM, Adelantado Rubio A, Hall A, Pappas G, Milletti G, Lee M, Johnsen LG, Guldberg P, Bartek J, Maya-Mendoza A (2023). NAD. Nature cell biology, 25(12), 1774-1786. https://doi.org/10.1038/s41556-023-01280-z Publication

Bohr VA (2026). Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage. Aging cell, 25(1), e70319. https://doi.org/10.1111/acel.70319 Publication

Lautrup S, Sinclair DA, Mattson MP, Fang EF (2019). NAD. Cell metabolism, 30(4), 630-655. https://doi.org/10.1016/j.cmet.2019.09.001 Publication

Berven H, Kverneng S, Sheard E, Søgnen M, Af Geijerstam SA, Haugarvoll K, Skeie GO, Dölle C, Tzoulis C (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nature communications, 14(1), 7793. https://doi.org/10.1038/s41467-023-43514-6 Publication

Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, Jayasena T, Grant R, Sachdev P (2019). Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Antioxidants & redox signaling, 30(2), 251-294. https://doi.org/10.1089/ars.2017.7269 Publication

Covarrubias AJ, Kale A, Perrone R, Lopez-Dominguez JA, Pisco AO, Kasler HG, Schmidt MS, Heckenbach I, Kwok R, Wiley CD, Wong HS, Gibbs E, Iyer SS, Basisty N, Wu Q, Kim IJ, Silva E, Vitangcol K, Shin KO, … Verdin E (2020). Senescent cells promote tissue NAD. Nature metabolism, 2(11), 1265-1283. https://doi.org/10.1038/s42255-020-00305-3 Publication

Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45(1), 29-43. https://doi.org/10.1007/s11357-022-00705-1 Publication

Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, Tobe K, Nakagawa T (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in nutrition, 9, 868640. https://doi.org/10.3389/fnut.2022.868640 Publication

Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences, 78(1), 90-96. https://doi.org/10.1093/gerona/glac049 Publication

Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD. Nature communications, 9(1), 1286. https://doi.org/10.1038/s41467-018-03421-7 Publication

Johnson S, Imai SI (2018). NAD. F1000Research, 7, 132. https://doi.org/10.12688/f1000research.12120.1 Publication

Conze D, Brenner C, Kruger CL (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific reports, 9(1), 9772. https://doi.org/10.1038/s41598-019-46120-z Publication

Gallagher C, Emmanuel OO (2026). NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057 Publication

Hong W, Mo F, Zhang Z, Huang M, Wei X (2020). Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism. Frontiers in cell and developmental biology, 8, 246. https://doi.org/10.3389/fcell.2020.00246 Publication

Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD. Frontiers in aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582 Publication

Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in aging neuroscience, 11, 257. https://doi.org/10.3389/fnagi.2019.00257 Publication

Gross CJ, Henderson LM (1983). Digestion and absorption of NAD by the small intestine of the rat. The Journal of nutrition, 113(2), 412-20. https://doi.org/10.1093/jn/113.2.412 Publication

Bogan KL, Brenner C (2008). Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annual review of nutrition, 28, 115-30. https://doi.org/10.1146/annurev.nutr.28.061807.155443 Publication

Majewski M, Kozlowska A, Thoene M, Lepiarczyk E, Grzegorzewski WJ (2016). Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 67(1), 3-19. https://pubmed.ncbi.nlm.nih.gov/27010891/ Publication

Romani M, Hofer DC, Katsyuba E, Auwerx J (2019). Niacin: an old lipid drug in a new NAD. Journal of lipid research, 60(4), 741-746. https://doi.org/10.1194/jlr.S092007 Publication